Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2017

Publisher Name :
Date: 11-Jul-2017
No. of pages: 101

According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2017'; Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.

The report 'Receptor Tyrosine Protein Kinase ERBB 3 - Pipeline Review, H2 2017' outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 5, 2, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Solid Tumor, Melanoma, Metastatic Breast Cancer, Lung Cancer, Pancreatic Cancer, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Ovarian Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Tumor, Endometrial Cancer, Epithelial Tumor, Ewing Sarcoma, Head And Neck Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Mesothelioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Nasopharyngeal Cancer, Neuroendocrine Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Tumor, Peritoneal Tumor, Skin Cancer, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Thyroid Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

  • The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H2 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Overview
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Celldex Therapeutics Inc
Daiichi Sankyo Company Ltd
Etubics Corp
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Hanmi Pharmaceuticals Co Ltd
Hummingbird Bioscience Pte Ltd
ImmunoGen Inc
MediaPharma Srl
Merrimack Pharmaceuticals Inc
Merus NV
Novartis AG
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Sorrento Therapeutics Inc
Symphogen A/S
Takis Srl
XuanZhu Pharma Co Ltd
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Drug Profiles
AV-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BA-0702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-3379 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elgemtumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETBX-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FCN-411 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2849330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HMBD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
huHER3-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
istiratumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lumretuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCLA-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize HER-3 for Breast and Pancrestic Cancers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MPEV-201959 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patritumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pirotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
poziotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seribantumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sym-013 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TK-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Dormant Products
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Discontinued Products
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Jun 19, 2017: Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018
Apr 03, 2017: AVEO Announces Milestone Payment from CANbridge for AV-203
Apr 03, 2017: Hummingbird Bioscience presents update on HMBD-001 at AACR in Washington DC
Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Mar 27, 2017: Merrimack to Present Data on Istiratumab (MM-141) at the 2017 American Association for Cancer Research Annual Meeting
Dec 08, 2016: Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
Dec 05, 2016: Spectrum Pharmaceuticals Presents Abstract on Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016
Oct 25, 2016: Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer
Sep 28, 2016: Merrimack to Present a Poster on Seribantumab (MM-121) at the European Society for Medical Oncology 2016 Congress
Aug 26, 2016: CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP - 5491)
Aug 11, 2016: CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody, CAN-017, for Esophageal Squamous Cell Cancer
Jul 06, 2016: FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Jun 06, 2016: Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2016: Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by AstraZeneca Plc, H2 2017
Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Pipeline by Celldex Therapeutics Inc, H2 2017
Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Pipeline by Etubics Corp, H2 2017
Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Pipeline by GlaxoSmithKline Plc, H2 2017
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017
Pipeline by ImmunoGen Inc, H2 2017
Pipeline by MediaPharma Srl, H2 2017
Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Pipeline by Merus NV, H2 2017
Pipeline by Novartis AG, H2 2017
Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H2 2017
Pipeline by Sorrento Therapeutics Inc, H2 2017
Pipeline by Symphogen A/S, H2 2017
Pipeline by Takis Srl, H2 2017
Pipeline by XuanZhu Pharma Co Ltd, H2 2017
Dormant Products, H2 2017
Dormant Products, H2 2017 (Contd..1), H2 2017
Dormant Products, H2 2017 (Contd..2), H2 2017
Discontinued Products, H2 2017
Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Global White Biotechnology Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 19-Sep-2018        Price: US 3480 Onwards        Pages: 122
    An entire branch of biotechnology, known as 'white biotechnology', is devoted to this. It uses living cells from yeast, moulds, bacteria and plants and enzymes to synthesize products that are easily degradable, require less energy and create less waste during their production. Scope of the Report: This report focuses on the White Biotechnology in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report c......
  • Global Transcriptomics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 115
    Transcriptomics incorporates the exploration and assortment of transcriptomes and finds diverse applications, chiefly in molecular genetics. The global transcriptomics market could see a whole lot of instances of new product launch. For example, Trio RNA-Seq launched by NuGEN Technologies, Inc. is particularly suited for low abundance transcripts applications as it offers an extremely sensitive whole transcriptomics solution. This innovation embodies three powerful technologies, viz. single prim......
  • 2015-2023 World Immune Checkpoint Inhibitors Market Research Report by Product Type, End-User / Application and Regions / Countries
    Published: 18-Sep-2018        Price: US 2800 Onwards        Pages: 101
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc)......
  • Global Cell Surface Markers Identification Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 139
    Cell Surface Markers Identification is used to identify and characterize cells. Scope of the Report: This report focuses on the Cell Surface Markers Identification in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The industry is a high-technology and high-profit industry, the research team maintain a v......
  • Global Cell-Based Assays Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 135
    This report studies the Cell-based Assays market, a Cell-based Assays is any method which is used to assess the cytotoxicity of a material. Scope of the Report: This report studies the Cell-Based Assays market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cell-Based Assays market by product type and applications/end industries.......
  • Global Nucleic Acid Labeling Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 17-Sep-2018        Price: US 3480 Onwards        Pages: 116
    Nucleic acid labeling techniques has wide range of applications in Life sciences industry. Nucleic acid Labeling is mainly used to identify proteins, DNA and RNA by using various Labeling techniques. Scope of the Report: This report studies the Nucleic Acid Labeling market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Nucleic A......
  • Viral Clearance Market by Application (Recombinant Proteins, Blood, Vaccines), End User (Pharmaceutical & Biotechnology Companies, CROs), Method (Viral Removal (Chromatography, Nanofiltration), Viral Inactivation (Low pH)) - Global Forecasts to 2023
    Published: 14-Sep-2018        Price: US 5650 Onwards        Pages: 159
    “The viral clearance market is projected to grow at a CAGR of 21.7% during the forecast period.” The global viral clearance market is expected to reach USD 724.5 million by 2023 from an estimated USD 271.2 million in 2018, at a CAGR of 21.7% during the forecast period. Growth in the pharmaceutical and biotechnology industries, increasing number of new drug launches, R&D investments in life science, advancements in nano filtration technology, and the hi......
  • 2015-2023 World Nucleic Acid Labeling Market Research Report by Product Type, End-User / Application and Regions / Countries
    Published: 13-Sep-2018        Price: US 2800 Onwards        Pages: 82
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc)......
  • 2018-2023 Global Glycomics/Glycobiology Market Report (Status and Outlook)
    Published: 12-Sep-2018        Price: US 4660 Onwards        Pages: 135
    In this report, LP Information studies the present scenario (with the base year being 2017) and the growth prospects of global Glycomics/Glycobiology market for 2018-2023. Glycomics is the comprehensive study of glycomes (the entire complement of sugars, whether free or present in more complex molecules of an organism), including genetic, physiologic, pathologic, and other aspects. Glycomics "is the systematic study of all glycan structures of a given cell type or organism" and is......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs